Parametric Portfolio Associates’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$18.3M Buy
239,583
+45,067
+23% +$3M 0.01% 1011
2021
Q4
$11.7M Sell
194,516
-3,102
-2% -$171K 0.01% 1277
2021
Q3
$11.1M Buy
197,618
+26,429
+15% +$1.52M 0.01% 1282
2021
Q2
$10.4M Sell
171,189
-16,383
-9% -$1.04M 0.01% 1363
2021
Q1
$13.1M Buy
187,572
+26,924
+17% +$1.92M 0.01% 1447
2020
Q4
$9.61M Sell
160,648
-25,667
-14% -$1.5M 0.01% 1604
2020
Q3
$11.2M Buy
186,315
+13,499
+8% +$784K 0.01% 1318
2020
Q2
$9.07M Buy
172,816
+28,185
+19% +$1.18M 0.01% 1463
2020
Q1
$4.85M Sell
144,631
-3,828
-3% -$159K ﹤0.01% 1753
2019
Q4
$6.72M Buy
148,459
+45,290
+44% +$1.92M ﹤0.01% 1829
2019
Q3
$3.93M Sell
103,169
-3,461
-3% -$138K ﹤0.01% 2196
2019
Q2
$4.64M Buy
106,630
+19,567
+22% +$831K ﹤0.01% 2068
2019
Q1
$3.31M Sell
87,063
-22,826
-21% -$891K ﹤0.01% 2290
2018
Q4
$4.73M Sell
109,889
-589
-0.5% -$27.5K ﹤0.01% 1940
2018
Q3
$5.43M Buy
110,478
+26,572
+32% +$1.15M ﹤0.01% 1961
2018
Q2
$2.69M Buy
83,906
+11,044
+15% +$381K ﹤0.01% 2472
2018
Q1
$2.27M Sell
72,862
-5,893
-7% -$210K ﹤0.01% 2532
2017
Q4
$3.6M Sell
78,755
-17,749
-18% -$703K ﹤0.01% 2167
2017
Q3
$3.62M Sell
96,504
-13,620
-12% -$548K ﹤0.01% 2128
2017
Q2
$5.25M Buy
110,124
+21,880
+25% +$1.02M 0.01% 1730
2017
Q1
$4.02M Buy
88,244
+32,009
+57% +$1.38M 0.01% 1940
2016
Q4
$1.82M Buy
56,235
+9,864
+21% +$329K ﹤0.01% 2433
2016
Q3
$1.59M Buy
46,371
+28,648
+162% +$1.12M ﹤0.01% 2504
2016
Q2
$598K Sell
17,723
-4,289
-19% -$211K ﹤0.01% 3091
2016
Q1
$1.17M Buy
22,012
+461
+2% +$27K ﹤0.01% 2815
2015
Q4
$1.66M Buy
21,551
+4,995
+30% +$283K ﹤0.01% 2376
2015
Q3
$680K Sell
16,556
-241
-1% -$14.8K ﹤0.01% 2564
2015
Q2
$1.19M Sell
16,797
-5,809
-26% -$457K ﹤0.01% 2665
2015
Q1
$2.01M Buy
22,606
+3,363
+17% +$341K ﹤0.01% 2241
2014
Q4
$1.71M Sell
19,243
-1,262
-6% -$119K ﹤0.01% 2333
2014
Q3
$1.99M Buy
20,505
+16,365
+395% +$1.59M ﹤0.01% 2079
2014
Q2
$380K Buy
+4,140
New +$315K ﹤0.01% 3387

Other funds holding PCRX